Pharvaris (PHVS) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Company background and therapeutic focus

• Celebrating its 10th anniversary, the company is advancing late-stage development for HAE, a rare genetic disorder causing painful and potentially life-threatening swelling attacks.

• The main unmet need is for a highly efficacious oral therapy, as most current treatments are injectables.

• Lead candidate deucrictibant is a B2 receptor antagonist, aiming for broad use in bradykinin-mediated angioedema.

Market landscape and strategy

• Prophylactic treatment now dominates the HAE market, with about 63% of patients on long-term prophylaxis, representing 80% of market value.

• Most patients use both on-demand and prophylactic therapies, highlighting the need for comprehensive treatment options.

• The company aims to differentiate with oral options for both on-demand and prophylactic settings.

Clinical trial results and product differentiation

• Phase III RAPIDe-3 trial for on-demand use met all primary and secondary endpoints, showing rapid symptom relief (1.28 hours vs. 12 hours for placebo) and early end of progression (17 minutes).

• 83% of attacks were resolved with a single dose, compared to 59% for a competitor, and the small softgel capsule offers ease of use.

• The oral formulation is positioned as faster and more convenient than both injectables and other orals.